February 23, 2021 Winnipeg, Manitoba 

Innotech Nutrition is entrenched in Science and has commissioned a laboratory research study (in-vitro) with Dr. Craig Meyers, at Penn State University. This week we received great news, the outcome of the study showed very promising results with our ColFlex Oral Spray products.

Both Innotech Nutrition “ColFlex” Oral Sprays inactivated 99-99.9% of infectious Human Coronavirus 229E, after a two-minute contact time, in the in-vitro studies (An in-vitro study occurs in a controlled laboratory environment). Human Coronavirus 229E (HCoV229E) is a strain of Coronavirus, which affects humans and bats and serves as one of the standards for coronavirus testing. HCoV229E is readily available and has genetic similarities to other Human Coronaviruses.

The oral spray products were also over 90% effective at inactivating the dried virus after a 60 second contact time. As in previous similar studies, the Penn State scientific team, led by Dr. Craig Meyers, prepared a standard laboratory test (viral inactivation assays) to replicate the interaction of the virus in the throat and oral cavities, with the oral spray product. Throat and oral cavities are major points of entry and transmission for human coronaviruses.

Although this in-vitro study has promising results, they are not in any way to be interpreted as a form of prevention for COVID-19. ColFlex does not prevent COVID-19.

This is a great first step, which may lead to further studies looking at potential additional benefits of ColFlex Oral Sprays.

A press release will be issued with details of the ColFlex oral spray study. We are anticipating a significant increase in demand for the products similar to the response from the successful outcome of the University of Manitoba ColFlex trial on antibacterial and safety data. Please consider this expected demand increase on your next order for ColFlex Arctic Mint and ColFlex Cinnamon Lemon. 

Healthy regards, Innotech Nutrition